Icon and Lilly sign agreement to manage clinical data management business

The agreement, which spans more than three dozen countries, excluding the US and Japan, will help to transform Lilly’s R&D organization as they seek to drive productivity, gain speed to market and lower drug development costs.

Jeff Kasher, vice president and COO of global clinical development at Lilly, said: “Lilly is eager to leverage Icon’s substantial, scalable clinical data management capabilities around the globe. Through this agreement, we take another significant step in our ongoing agenda to increase flexibility, reduce fixed cost, and focus internal resources on core capabilities.”